To further investigate the expression of NE and β-catenin in ovarian cancer and analyze their clinicopathological significance, the expression levels of NE and β-catenin were assayed in 17 ovarian cysts, 38 serous carcinomas, 14 mucous carcinomas, and 19 other pathological subtypes of ovarian cancer by tumor tissue arrays (Table 1). This evidence concerns the gene ELANE and serous adenocarcinoma.